At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 220 enrolled

Drug / intervention

Desloratadine +1 moredrug

Likely dose

Desloratadine 2.5 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00780403

NCT00780403Phase 4Completed

Compare CT.gov

A Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications

Organon and Co·interventional·Posted Oct 27, 2008·Updated Feb 9, 2022

In Brief

A Phase 4 clinical trial evaluating Desloratadine and Zyrtec® (cetirizine) for Allergies. Completed, enrolled 220 participants.

Detailed Summary

The primary objective of this study was to determine whether children ages 6-11 years prefer desloratadine RediTabs (2.5 mg) or a marketed competitor (Zyrtec® 5 mg Chewable Tablets). The secondary objectives of this study were to compare acceptance of the two attributes, taste and feeling in the mouth, of desloratadine 2.5 mg RediTabs and Zyrtec® 5 mg Chewable Tablets

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAllergies

Countries--

Collaborators--

Timeline

Phase 4CompletedFinished

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartAug 2005

Primary CompletionOct 2005

First PostedOct 2008

TodayJul 2026

First PostedOct 27, 2008

Enrollment StartAug 1, 2005

Primary CompletionOct 1, 2005

TodayJul 2, 2026

Enrollment to primary: 2 monthsPosted 17.7 years ago

Interventions

Desloratadinedrug

desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day

Zyrtec® (cetirizine)drug

Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day